WT1 and myelodysplastic syndrome: Furthermore, monitoring of disease and response kinetics by PB WT1-mRNA expression to guide therapeutic decisions may also be used in MDS patients treated with other therapies such as hypomethylating agents25 or proteasome inhibitors11,26.